Quest Diagnostics to Offer Natera's Prenatal Test | GenomeWeb

NEW YORK (GenomeWeb News) – Quest Diagnostics today said that it has signed an agreement to offer a non-invasive prenatal test developed by Natera.

The Panorama test uses cell-free fetal DNA in circulating maternal blood to screen for trisomy 21, 18, and 13, as well as monosomy X. It can be used as early as the ninth week of pregnancy, the firms said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.